Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Type 2 Diabetes and Exercise - A Pilot Study
This study is currently recruiting participants.
Verified by Bayside Health, April 2008
Sponsors and Collaborators: Bayside Health
International Diabetes Institute, Australia
Baker Heart Research Institute
Information provided by: Bayside Health
ClinicalTrials.gov Identifier: NCT00666861
  Purpose

A randomised, cross-over trial targeting a small sample of older (age 45-65 years) overweight adults with type 2 diabetes the aims of this pilot study are to:

  1. Determine the feasibility of investigating the acute effects of prolonged sedentary behaviour (sitting) in this target group.
  2. Compare the acute effects of a single prolonged (8 hour) bout of sedentary behaviour (sitting) on glucose and triglyceride concentrations and key muscle and adipose regulatory enzymes to a similar bout of sedentary behaviour combined with intermittent bouts of light-intensity activity.

Condition
Type 2 Diabetes

MedlinePlus related topics: Diabetes
Drug Information available for: Dextrose Lipids
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort, Cross-Sectional
Official Title: Understanding the Acute Effects of Prolonged Sedentary Behaviour (Sitting) on Post-Meal Glucose and Lipids - A Pilot Study

Further study details as provided by Bayside Health:

Biospecimen Retention:   Samples Without DNA

Biospecimen Description:

Plasma samples


Estimated Enrollment: 20
Study Start Date: April 2008
Estimated Study Completion Date: April 2009
Detailed Description:

The proposed study will involve a randomised cross-over experimental trial conducted in the laboratory setting in older overweight adults with type 2 diabetes. Participants will receive both of the acute testing conditions in a randomised manner.

Study design: Randomised cross-over pilot trial of 20 overweight/obese older adults with diet-controlled type 2 diabetes involving 2 acute treatment conditions, with a one-week wash-out period between testing conditions (Figure 1 a).

Setting: Acute, supervised laboratory setting within the Alfred and Baker Heart Institute Medical Unit.

Outcomes: We will measure acute responses in laboratory-measured plasma glucose & triglyceride levels (every 60 mins) and glucose concentrations determined from continuous glucose monitoring (CGMS).

  Eligibility

Ages Eligible for Study:   45 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with Type 2 Diabetes

Criteria

Inclusion Criteria:

  1. Diet controlled Diabetes
  2. Overweight (BMI > 27 kg/m2 but <40 kg/m2)

Exclusion Criteria:

  1. Hypoglycaemic Agents
  2. Lipid Lowering Agents
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00666861

Contacts
Contact: Miriam M Clayfield +61-3-9076 2948 m.clayfield@alfred.org.au

Locations
Australia, Victoria
Alfred Hospital Recruiting
Melbourne, Victoria, Australia, 3004
Contact: Miriam M Clayfield     +61-3-9076 2948     m.clayfield@alfred.org.au    
Sponsors and Collaborators
Bayside Health
International Diabetes Institute, Australia
Baker Heart Research Institute
Investigators
Principal Investigator: Bronwyn A Kingwell, PhD Baker Heart Research Institute
  More Information

Responsible Party: Baker Heart Research Institute ( Assoc/Prof Bronwyn Kingwell - Executive Director Science Policy abd Head, Clinical Physiology )
Study ID Numbers: 290/07
Study First Received: April 23, 2008
Last Updated: April 24, 2008
ClinicalTrials.gov Identifier: NCT00666861  
Health Authority: Australia: National Health and Medical Research Council

Study placed in the following topic categories:
Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders

ClinicalTrials.gov processed this record on January 16, 2009